Braidwell »

Rapt Therapeutics shares owned by Braidwell

Quarter-by-quarter ownership of Rapt Therapeutics (RAPT) shares owned by Braidwell from 13F filings

Historical chart of Braidwell investment in Rapt Therapeutics

Tip: Access up to 7 years of quarterly data

All positions including Rapt Therapeutics held by Braidwell consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Rapt Therapeutics by Braidwell

Quarter filed Position value Share count Share price at filing
2025-12-31 $32M 930k 33.87

More positions owned by Braidwell

Caris Life Sciences (CAI)
Guardant Health Debt 1.250% 2/1 (Principal)
Edgewise Therapeutics (EWTX)
Repligen Corp Note 1.000%12/1 (Principal)
Neurocrine Biosciences (NBIX)
Glaukos (GKOS)
Neogenomics Note 0.250% 1/1 (Principal)
Nuvalent Inc-a (NUVL)
Xenon Pharmaceuticals (XENE)
Cg Oncology (CGON)
Irhythm Technologies Note 1.500% 9/0 (Principal)
Hinge Health Cl A (HNGE)
Align Technology (ALGN)
Kodiak Sciences (KOD)
Soleno Therapeutics (SLNO)

View all positions for Braidwell

Top funds holding Rapt Therapeutics

TCG Crossover Management
Foresite Capital Management VI
Rtw Investments
Vanguard Group
OrbiMed Advisors
Braidwell
Ikarian Capital
Boone Capital Management
Deep Track Capital
Caligan Partners
State Street Corporation
Nantahala Capital Management
Siren
Redmile Group
Soleus Capital Management

View all funds holding Rapt Therapeutics